An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building its ...

Neoadjuvant semaglutide showed no benefit in weight loss, diabetes remission or safety in a cohort of patients who underwent ...

Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

While gastrointestinal issues are the most common side effects, a recent study by the University of British Columbia linked ...

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Semaglutide was found to reduce the occurrence of major adverse cardiovascular events (MACE) by 20% in patients with a ...